Atropine is one of the oldest medications in eye care, traditionally used at full strength to dilate the pupil during eye exams. At much lower concentrations, atropine eye drops have been shown to slow the progression of myopia in growing children. The drops are placed in the child's eyes once daily, typically at bedtime, and the treatment continues throughout the years when the eyes are actively growing and myopia is most likely to worsen.
The concept is straightforward: a single daily drop that may reduce how nearsighted a child becomes by adulthood. For parents watching their child's prescription increase year after year, this represents a proactive step that goes beyond simply updating the glasses.
Myopia is more than an inconvenience that requires glasses or contacts. Higher levels of nearsightedness are associated with increased risk of serious eye conditions later in life, including retinal detachment, glaucoma, and myopic macular degeneration. According to the National Eye Institute, 42 percent of Americans are now nearsighted, up from 25 percent in the 1970s. This rising prevalence makes treatments that slow myopia progression increasingly important for protecting long-term eye health, especially in children whose eyes are still developing.
The exact mechanism by which low-dose atropine slows myopia is still being studied, but researchers believe it acts on receptors in the sclera, the white outer shell of the eye. During myopia development, the eyeball grows too long from front to back. Atropine appears to interact with signaling pathways that influence this elongation, slowing the rate at which the eye stretches. The effect is gentle and does not change the child's current prescription. It simply reduces how quickly the prescription worsens over time.
According to a peer-reviewed study published in 2024, the LAMP clinical trial found that 0.05 percent atropine eye drops slowed myopia progression by more than 50 percent over five years in children aged 4 to 12. This large, well-designed trial provided some of the strongest evidence to date that low-dose atropine is both effective and well tolerated over an extended treatment period. The results have made atropine one of the most widely recommended myopia management tools worldwide.
According to published clinical trials, atropine for myopia management has been studied at several low-dose concentrations. Lower doses produce fewer side effects, such as pupil dilation and light sensitivity, but may also have a smaller slowing effect. Higher doses within the low-dose range have shown stronger efficacy but may cause more noticeable pupil dilation. Your eye doctor will recommend the concentration that balances the best slowing effect with the fewest side effects for your child.
Low-dose atropine has been studied extensively in clinical trials lasting up to five years, and the safety data is reassuring. At the concentrations used for myopia management, most children experience few or no side effects. The most common effects are mild pupil dilation and slight sensitivity to bright light, which are typically manageable with sunglasses or a hat. These effects are much less pronounced than those associated with the full-strength atropine used during eye exams.
At Insight Vision Optometry, Las Vegas, treatment begins with a comprehensive myopia evaluation. Your eye doctor measures your child's current prescription, assesses the rate of progression using historical records, and measures the axial length of the eye, which is the most precise indicator of myopia progression. This baseline data is essential for tracking how well the treatment works over the following months and years.
The drops are administered once daily, usually at bedtime to minimize any daytime effects on the pupil. A single drop is placed in each eye. For young children, it often helps to have the child lie down with their eyes closed, place the drop in the inner corner of the eye, and then have them open their eyes to let the drop flow in. Your eye doctor will demonstrate the technique and provide tips for making the process as smooth as possible.
Your child will return for follow-up visits every three to six months. At each visit, the eye doctor remeasures the prescription and axial length to track whether myopia progression has slowed compared to the expected rate without treatment. These measurements provide objective data that guides treatment decisions. If the current concentration is not providing adequate slowing, your eye doctor may adjust the dose or recommend adding a complementary treatment.
Low-dose atropine for myopia management is not available as a standard product at most pharmacies. It is typically prepared by a compounding pharmacy that formulates the drops at the specific concentration prescribed by your eye doctor. Your eye doctor will provide a prescription and help connect you with a compounding pharmacy that prepares the drops to the required specifications. The drops are usually supplied as a monthly or multi-month supply.
If your child experiences mild pupil dilation from the atropine, they may be more sensitive to bright light during outdoor activities. In Las Vegas, where sunshine is intense for much of the year, sunglasses with UV protection are important for all children and especially useful for those on atropine. Photochromic lenses that darken automatically in sunlight are another practical option. Most children on low-dose atropine find the light sensitivity manageable and do not report significant disruption to their daily activities.
Atropine treatment typically continues throughout the active growth years, often until the mid to late teens when eye growth naturally slows. Stopping treatment too early can result in a rebound effect where myopia progression temporarily accelerates. Your eye doctor will work with you to determine when it is appropriate to gradually taper and discontinue the drops, based on your child's age, progression pattern, and overall eye health. Families from Henderson, Enterprise, Paradise, Spring Valley, and across the region rely on this ongoing guidance from our team.
Low-dose atropine does not correct myopia or change the current prescription. Your child will still need their glasses or contact lenses for clear vision. What atropine does is slow the rate at which the prescription worsens over time. The goal is to reduce the total amount of myopia your child develops by adulthood.
The available research, including studies lasting up to five years, has not identified significant long-term risks from low-dose atropine use in children. The most common side effects are mild pupil dilation and light sensitivity, which resolve when treatment is stopped. Your eye doctor monitors your child's eyes at regular intervals to ensure the treatment remains safe and appropriate throughout the duration of use.
If atropine is discontinued abruptly, some studies have observed a rebound effect where myopia progression temporarily accelerates before returning to its natural rate. To minimize this, your eye doctor will typically recommend a gradual tapering schedule rather than stopping all at once. The timing of discontinuation is based on your child's age and current rate of eye growth.
Yes. Combining low-dose atropine with orthokeratology lenses is a well-recognized approach in myopia management. The two treatments work through different mechanisms, so using them together may provide a stronger slowing effect than either treatment alone. Your eye doctor will determine whether combination therapy is appropriate based on your child's individual progression pattern and response to treatment.
Atropine can be started as early as age four or five with confirmed progressive myopia. The ideal starting age depends on when myopia is first diagnosed, how quickly it is progressing, and the family history of nearsightedness. Children with a strong family history and early onset of myopia may benefit most from starting treatment early. Your eye doctor will evaluate your child and recommend the right time to begin based on their specific situation.
